PATENT CLAIM ANALYSIS

Application Number: 15875929
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["548", "537000"]

Abstract:
Inhibitors of HBV replication of Formula (ID) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, R a  to R d  and R 4  to R 6  have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

Claim (Index 16):
A method of treating HBV infection in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound of Formula (ID) or a stereoisomer or tautomeric form thereof, wherein: each X is independently CR 7 ; R a , R b  and R c  are each independently selected from the group consisting of hydrogen, fluoro, bromo, chloro, \u2014CHF 2 , \u2014CF 2 -methyl, \u2014CH 2 F, \u2014CF 3 , \u2014OCF 3 , \u2014CN, C 1 -C 3 alkyl and C 3 -C 4 cycloalkyl; R d  is hydrogen or fluoro; R 4  is hydrogen, C 1 -C 3 alkyl or C 3 -C 4 cycloalkyl; R 5  is hydrogen; R 6  is selected from the group consisting of C 2 -C 6 alkyl, C 1 -C 4 alkyl-R 8  optionally substituted with one or more fluoro, C 1 -C 4 alkyl-R 9  optionally substituted with one or more fluoro, and a 3-7 membered mono or polycyclic saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring or C 2 -C 6 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, \u2014OH, fluoro, oxo, R 9 , R 10  and C 1 -C 4 alkyl optionally substituted with R 10 ; R 7  is selected from the group consisting of hydrogen, \u2014CN, fluoro, chloro, bromo, \u2014CHF 2 , \u2014CF 2 -methyl, \u2014CH 2 F, \u2014CF), C 1 -C 3 alkyl optionally substituted with methoxy, C 2 -C 3 alkenyl and C 3 -C 4 cycloalkyl; R 8  is a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally substituted with one or more C 1 -C 4 alkyl optionally substituted with R 10 ; R 9  is selected from the group consisting of C 1 -C 4 alkyloxy, \u2014SO 2 -methyl, \u2014C(\u2550O)\u2014OR 11  and \u2014C(\u2550O)\u2014N(R 11 ) 2 ; R 10  is selected from the group consisting of \u2014CN, \u2014OH, fluoro, \u2014CHF 2 , \u2014CH 2 F and \u2014CF 3 ; R 11  is hydrogen or C 1 -C 3 alkyl; or a pharmaceutically acceptable salt or a solvate thereof wherein such compound is not

Metadata:
- Claim Count in Document: 47.0
- Percentile: 86.0
- Lexical Diversity: 1.33333
- Patent Class: 548.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14891895', '14907109', '15031493', '14782308', '15177641']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7900209192333981
- 35 USC 102 Novelty (BERT): 0.5546527113332661
- Combined Prediction Score: 0.7664840984433849
- Mean Citation Score: 401.944878
- Max Citation Score: 458.7033
- Similarity Product: 326.7708618022085

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test